<DOC>
	<DOCNO>NCT01796002</DOCNO>
	<brief_summary>Primary objective study compare efficacy romidepsin administer CHOP versus CHOP alone subject previously untreated peripheral T-cell lymphoma ( PTCL ) term progression-free survival ( PFS ) assess accord Response criterion malignant lymphoma 1999 RAC .</brief_summary>
	<brief_title>Efficacy Safety Romidepsin CHOP v CHOP Patients With Untreated Peripheral T-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>1 . Males females 18 year age 80 year age . 2 . Understand voluntarily sign informed consent document prior study related assessments/procedures conduct . 3 . Able adhere study visit schedule protocol requirement . 4 . Patients histologically proven peripheral Tcell lymphoma ( PTCL ) , previously treat ; follow subtypes define WHO classification ( 2008 ; 2011 ) may include , whatever Ann Arbor stage ( I IV ) : a. Nodal type : i. PTCL , otherwise specify ii . Angioimmunoblastic Tcell lymphoma iii . Anaplastic large cell lymphoma , ALKnegative type b. Extranodal type : i. Enteropathyassociated Tcell lymphoma ii . Hepatosplenic Tcell lymphoma iii . Subcutaneous panniculitislike Tcell lymphoma iv . Primary cutaneous gammadelta Tcell lymphoma v. Primary cutaneous CD8+ aggressive epidermotropic lymphoma vi . Primary cutaneous CD4+ small/medium Tcell lymphoma c. Other non classifiable peripheral Tcell lymphoma 5 . ECOG performance status 0 , 1 2 6 . Negative pregnancy test female childbearing potential ( FCBP ) 7 . Female patient child bear potential must use effective method birth control ( i.e . hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide abstinence ) treatment period 1 month thereafter ; Males must use effective method birth control treatment period 3 month thereafter . 8 . Life expectancy ≥ 90 day ( 3 month ) . 1 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent patient participate study . 2 . Any condition confound ability interpret data study . 3 . Other type lymphoma , e.g . Bcell lymphoma 4 . The following type T cell lymphoma : 1 . Adult Tcell lymphoma/leukemia ( HTLV1 relate Tcell lymphoma ) 2 . Extranodal Tcell/NKcell lymphoma , nasal type 3 . Anaplastic large cell lymphoma , ALKpositive type 4 . Cutaneous T cell lymphoma ( mycosis fungoid , Sézary syndrome ) 5 . Primary cutaneous CD30+ Tcell lymphoproliferative disorder 6 . Primary cutaneous anaplastic Tcell lymphoma 5 . Previous treatment PTCL immunotherapy chemotherapy except shortterm corticosteroid ( duration ≤ 8 day ) randomization 6 . Previous radiotherapy PTCL except localize one lymph node area 7 . Patients plan autologous allogeneic transplant consolidation first line 8 . Central nervous system meningeal involvement 9 . Contraindication drug contain chemotherapy regimen , 10 . Subjects HIV positivity 11 . Subjects active hepatitis B C. Chronic carrier hepatitis B without HBV DNA positive blood eligible . Subjects nonactive hepatitis C ( normal transaminase ) eligible . 12 . Any following laboratory abnormality , except secondary lymphoma : 1 . Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm3 ( 1.5 x 109/L ) , 2 . Platelet count &lt; 100,000/mm3 ( 100 x 109/L ) , &lt; 75,000/mm3 bone marrow involve , 3 . Serum SGOT/AST SGPT/ALT ≥ 3.0 x upper limit normal ( ULN ) , 4 . Serum total bilirubin &gt; 2 x ULN , except case hemolytic anemia , 5 . K+ Mg2+ level &lt; LLN , except correct per protocol guidance begin romidepsin infusion 13 . Serum creatinine &gt; 2.0 x ULN 14 . Prior history malignancy lymphoma ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast untreated prostatic cancer without plan treatment ) unless patient free disease ≥ 3 year 15 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent patient signing informed consent form 16 . Any known cardiac abnormality : 1 . Patients congenital long QT syndrome 2 . Corrected QT interval &gt; 480 msec ( use Fridericia formula ) 3 . Myocardial infarction within 6 month cycle 1 day 1 4 . History concomitant significant cardiovascular disease 5 . Ejection fraction &lt; 45 % MUGA scan echocardiogram ; 17 . Concomitant use drug may cause significant prolongation QTc 18 . Patients receive 200 mg/m2 doxorubicin 19 . Concomitant use strong CYP3A4 inhibitor 20 . Concomitant use therapeutic warfarin due potential drug interaction . Use low dose warfarin another anticoagulant maintain patency venous access port cannula permit . 21 . Clinically significant active infection 22 . Use standard experimental anticancer drug therapy within 28 day initiation ( Day 1 ) study drug 23 . Pregnant lactate female woman childbearing potential willing use adequate method birth control duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PTCL</keyword>
</DOC>